Search

Progeria is a globally noticed rare genetic disorder manifested by premature aging with no effective treatment. Under these circumstances, farnesyltransferase inhibitors (FTIs) are marked as promising drug candidates. Correspondingly, a pharmacophore model was generated exploiting the features of lonafarnib. The selected pharmacophore model was allowed to screen the InterBioScreen natural compound database to retrieve the potential lead candidates. A series of filtering steps were applied to assess the drug-likeness of the compounds. The obtained compounds were advanced to molecular docking employing the CDOCKER module available with Discovery Studio (DS). Subsequently, three compounds (Hits) have displayed a higher dock score and demonstrated key residue interactions with stable molecular dynamics simulation results compared to the reference compound. Taken together, we therefore put forth three identified Hits as FTIs that may further serve as chemical spaces in designing new compounds.

Dihydrofolate reductase (DHFR) is an essential cellular enzyme and thereby catalyzes the reduction of dihydrofolate to tetrahydrofolate (THF). In cancer medication, inhibition of human DHFR (hDHFR) remains a promising strategy, as it depletes THF and slows DNA synthesis and cell proliferation. In the current study, ligand-based pharmacophore modeling identified and evaluated the critical chemical features of hDHFR inhibitors. A pharmacophore model (Hypo1) was generated from known inhibitors of DHFR with a correlation coefficient (0.94), root mean square (RMS) deviation (0.99), and total cost value (125.28). Hypo1 was comprised of four chemical features, including two hydrogen bond donors (HDB), one hydrogen bond acceptor (HBA), and one hydrophobic (HYP). Hypo1 was validated using Fischer’s randomization, test set, and decoy set validations, employed as a 3D query in a virtual screening at Maybridge, Chembridge, Asinex, National Cancer Institute (NCI), and Zinc databases. Hypo1-retrieved compounds were filtered by an absorption, distribution, metabolism, excretion, and toxicity (ADMET) assessment test and Lipinski’s rule of five, where the drug-like hit compounds were identified. The hit compounds were docked in the active site of hDHFR and compounds with Goldfitness score was greater than 44.67 (docking score for the reference compound), clustering analysis, and hydrogen bond interactions were identified. Furthermore, molecular dynamics (MD) simulation identified three compounds as the best inhibitors of hDHFR with the lowest root mean square deviation (1.2 Å to 1.8 Å), hydrogen bond interactions with hDHFR, and low binding free energy (−127 kJ/mol to −178 kJ/mol). Finally, the toxicity prediction by computer (TOPKAT) affirmed the safety of the novel inhibitors of hDHFR in human body. Overall, we recommend novel hit compounds of hDHFR for cancer and rheumatoid arthritis chemotherapeutics.

It has been suggested that plant phytochromes are autophosphorylating serine/threonine kinases. However, the biochemical properties and functional roles of putative phytochrome kinase activity in plant light signalling are largely unknown. Here, we describe the biochemical and functional characterization of Avena sativa phytochrome A (AsphyA) as a potential protein kinase. We provide evidence that phytochrome-interacting factors (PIFs) are phosphorylated by phytochromes in vitro. Domain mapping of AsphyA shows that the photosensory core region consisting of PAS-GAF-PHY domains in the N-terminal is required for the observed kinase activity. Moreover, we demonstrate that transgenic plants expressing mutant versions of AsphyA, which display reduced activity in in vitro kinase assays, show hyposensitive responses to far-red light. Further analysis reveals that far-red light-induced phosphorylation and degradation of PIF3 are significantly reduced in these transgenic plants. Collectively, these results suggest a positive relationship between phytochrome kinase activity and photoresponses in plants., Phytochromes regulate plant responses to environmental light conditions but despite extensive research the initial events in phytochrome signaling remain uncertain. Here, Shin et al. provide evidence that phytochrome phosphorylates target proteins via kinase activity in the N-terminal core domain.

Progeria is a rare genetic disorder characterized by premature aging that eventually leads to death and is noticed globally. Despite alarming conditions, this disease lacks effective medications; however, the farnesyltransferase inhibitors (FTIs) are a hope in the dark. Therefore, the objective of the present article is to identify new compounds from the databases employing pharmacophore based virtual screening. Utilizing nine training set compounds along with lonafarnib, a common feature pharmacophore was constructed consisting of four features. The validated Hypo1 was subsequently allowed to screen Maybridge, Chembridge, and Asinex databases to retrieve the novel lead candidates, which were then subjected to Lipinski’s rule of 5 and ADMET for drug-like assessment. The obtained 3,372 compounds were forwarded to docking simulations and were manually examined for the key interactions with the crucial residues. Two compounds that have demonstrated a higher dock score than the reference compounds and showed interactions with the crucial residues were subjected to MD simulations and binding free energy calculations to assess the stability of docked conformation and to investigate the binding interactions in detail. Furthermore, this study suggests that the Hits may be more effective against progeria and further the DFT studies were executed to understand their orbital energies.

3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) catalyzes the conversion of HMG-CoA to mevalonate using NADPH and the enzyme is involved in rate-controlling step of mevalonate. Inhibition of HMGR is considered as effective way to lower cholesterol levels so it is drug target to treat hypercholesterolemia, major risk factor of cardiovascular disease. To discover novel HMGR inhibitor, we performed structure-based pharmacophore modeling combined with molecular dynamics (MD) simulation. Four HMGR inhibitors were used for MD simulation and representative structure of each simulation were selected by clustering analysis. Four structure-based pharmacophore models were generated using the representative structure. The generated models were validated used in virtual screening to find novel scaffolds for inhibiting HMGR. The screened compounds were filtered by applying drug-like properties and used in molecular docking. Finally, four hit compounds were obtained and these complexes were refined using energy minimization. These compounds might be potential leads to design novel HMGR inhibitor.

Certain tRNA synthetases have developed highly accurate molecular machinery to discriminate their cognate amino acids. Those aaRSs achieve their goal via editing reaction in the Connective Polypeptide 1 (CP1). Recently mutagenesis studies have revealed the critical importance of residues in the CP1 domain for editing activity and X-ray structures have shown binding mode of noncognate amino acids in the editing domain. To pursue molecular mechanism for amino acid discrimination, molecular modeling studies were performed. Our results suggest that aaRS bind the noncognate amino acid more tightly than the cognate one. Finally, by comparing binding conformations of the amino acids in three systems, the amino acid binding mode was elucidated and a discrimination mechanism proposed. The results strongly reveal that the conserved threonines are responsible for amino acid discrimination. This is achieved through side chain interactions between T252 and T247/T248 as well as between those threonines and the incoming amino acids., {"references":["Carter Jr., C. W.,\"Cognition, mechanism, and evolutionary relationships\nin aminoacyl-tRNAsynthetases\",Annu. Rev. Biochem,vol. 62, pp.\n715-748, 1993.","Martinis, S.A., and Schimmel, P.,\"Escherichia coli and Salmonella\nCellular and Molecular Biology\", 2nd Ed., ASM, Neidhardt FC,\nWashington DC, 1996.","Giege, R., Sissler, M., Florentz, C.,\"Universal rules and idiosyncratic\nfeatures in tRNA identity\",Nucleic Acids Res,vol. 26, pp.\n5017-5035,1998.","Fersht, A. R., Kaethner, M. M., \"Mechanism of aminoacylation of tRNA.\nProof of the aminoacyladenylate pathway for the isoleucyl- and\ntyrosyl-tRNAsynthetases from Escherichia coli K12\", Biochemistry,vol.\n15, pp. 818-823,1976.","Pauling, L., Festschrift f├╝r Prof. Dr. Arthur Stoll, BirkhauserVerlag, Basel\n1958.","Loftfield, R. B.,\"The Frequency of errors in protein\nbiosynthesis\",Biochem. J.,vol. 89, pp. 82-92, 1963.","Eldred, E. W., Schimmel, P.,\"Rapid deacylation by isoleucyl transfer\nribonucleic acid synthetase of isoleucine-specific transfer ribonucleic acid\naminoacylated with valine\", J. Biol. Chem.,vol. 247, pp. 2961-2964,\n1972.","Schmidt, E., Schimmel, P.,\"Insights into editing from an\nile-tRNAsynthetase structure with tRNAile and mupirocin\",Science,vol.\n285, pp. 1074-1077, 1994.","Hale, S. P., Schimmel, P.,\"Protein synthesis editing by a DNA\naptamer\",Proc. Natl. Acad. Sci. USA,vol. 93, pp. 2755-2758, 1996.\n[10] Fersht, A. R., Kaethner, M. M.,\"Enzyme hyperspecificity. Rejection of\nthreonine by the valyltRNAsynthetase by misacylation and hydrolytic\nediting\",Biochemistry,vol. 15, pp. 3342-3346, 1976.\n[11] Fersht, A. R.,\"Editing mechanisms in protein synthesis. Rejection of\nvaline by the isoleucyl-tRNAsynthetase\",Biochemistry,vol. 16, pp.\n1025-1030, 1977.\n[12] Fersht, A. R.,\"Enzyme Structure and Mechanism\", Freeman, San\nFrancisco, 1997.\n[13] Fersht, A. R., Dingwall C.,\"Establishing the misacylation/deacylation of\nthe tRNA pathway for the editing mechanism of prokaryotic and\neukaryotic valyl-tRNAsynthetases\",Biochemistry,vol. 18, pp. 1238-1245,\n1979.\n[14] Fersht, A. R.,\"Sieves in sequence\",Science,vol. 280, pp. 541, 1998.\n[15] Nureki, O., Vassylyev D. G., Tateno, M., Shimada, A., Nakama, T., Fukai,\nS., Konno, M., Hendrickson, T.L., Schimmel, P., Yokoyama, S.,\"Enzyme\nstructure with two catalytic sites for double-sieve selection of\nsubstrate\",Science,vol. 280, pp. 578-582, 1998.\n[16] Silvian, L. F., Wang, J., Steitz, T. A.,\"Insights into editing from an\nile-tRNAsynthetase structure with tRNAile and mupirocin\",Science,vol.\n285, pp. 1074-1077, 1999.\n[17] Fukai, S., Nureki, O., Sekine, S., Shimada, A., Tao, J., Vassylyev, D. G.,\nYokoyama, S.,\"Structural basis for double-sieve discrimination of L-Val\nfrom L-Ile and L-threonine by the complex of tRNAVal and\nvalyl-tRNAsynthetase\",Cell,vol. 103, pp. 793-893, 2000.\n[18] Cusack, S., Yaremchuk, A., Tukalo, M.,\"The 2 Å crystal structure of\nleucyl-tRNAsynthetase and its complex with a leucyl-adenylate\nanalogue\",EMBO J.,vol. 19, pp. 2351-2631, 2000.\n[19] Lincecum Jr., T. L., Tukalo, M,, Yaremchuk, A., Mursinna, R. S.,\nWilliams, A. M., Sproat, B. S., Van Den Eynde, W., Link, A., Van\nCalenbergh, S., Grotli, M., Martinis, S. A., Cusack, S.,\"Structural and\nmechanistic basis of pre- and posttransfer editing by\nleucyl-tRNAsynthetase\",Mol. Cell,vol. 11, pp. 951-963, 2003.\n[20] Bishop, A. C., Nomanbhoy, T. K., Schimmel, P., \"locking site-to-site\ntranslocation of a misactivated amino acid by mutation of a class I\ntRNAsynthetase\", Proc. Natl. Acad. Sci. USA,vol. 99, pp. 585-590, 2002.\n[21] Hendrickson, T. L., Nomanbhoy, T. K., Schimmel, P.,\"Errors from\nselective disruption of the editing center in a\ntRNAsynthetase\",Biochemistry,vol. 39, pp. 8180-8186,2000.\n[22] Mursinna, R. S., Lincecum, T. L., Martinis, S. A.,\"A conserved threonine\nwithin Escherichia coli leucyl-tRNAsynthetase prevents hydrolytic\nediting of leucyl-tRNALeu\",Biochemistry,vol. 40, pp. 5376-5381, 2001.\n[23] Mursinna, R. S., Martinis, S. A., \"Rational design to block amino acid\nediting of a tRNAsynthetase\",J. Am. Chem. Soc.,vol. 124, pp. 7286-7287,\n2002.\n[24] Mursinna, R. S., Lee, K. W., Briggs, J. M., Martinis, S. A.,\"Molecular\ndissection of a critical specificity determinant within the amino acid\nediting domain of leucyl-tRNAsynthetase\",Biochemistry,vol. 43, pp.\n155-165, 2004.\n[25] Lee, K. W., Briggs, J. M.,\"Molecular modeling study of the editing active\nsite of Escherichia coli leucyl-tRNAsynthetase: two amino acid binding\nsites in the editing domain\",Proteins: Struct. Funct. Bioinformatics,vol.\n54,pp. 693-704, 2004.\n[26] Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J.,\nSwaminathan, S., Karplus, M.,\"CHARMM: A program for\nmacromolecular energy, minimisation and dynamics calculations\",J.\nComp. Chem.,vol. 4, pp. 187-217, 1983.\n[27] Kale, L., Skeel, R., Bhandarkar, M., Brunner, R., Gursoy, A., Krawetz, N.,\nPhillips, J., Shinozaki, A., Varadarajan, K., Schulten, K.,\"NAMD2:\nGreater Scalability for Parallel Molecular Dynamics\",J. Comp. Phys.,vol.\n151, pp. 283-312,1999.\n[28] Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A.,\nHaak, J. R.,\"Molecular dynamics with coupling to an external bath\",J.\nChem. Phys.,vol. 81, pp. 3684-3690,1984.\n[29] Amadei, A., Linssen, A. B. M., Berendsen, H. J. C., \"Essential dynamics\nof proteins\",Proteins: Struct. Funct. Genetics,vol. 17, pp. 412-425,1993.\n[30] Vriend, G.,\"WHAT IF: A molecular modeling and drug design\nprogram\",J. Mol. Graph.,vol. 8, pp. 52-56, 1990.\n[31] Aqvist, J., Medina, C., Samuel, J. E.,\"A new method for predicting\nbinding affinity in computer-aided drug design\",Protein Eng.,vol. 7, pp.\n385-391, 1994.\n[32] Hansson, T., Åqvist, J.,\"Estimation of binding free energies for HIV\nproteinase inhibitors by molecular dynamics simulations\",Protein\nEng.,vol. 8, pp. 1137-1144,1995.\n[33] Aqvist, J.,\"Calculation of absolute binding free energies for charged\nligands and effects of long-range electrostatic interactions\",J. Comp.\nChem.,vol. 17, pp. 1587-1597,1996.\n[34] Srinivasan, J., Cheatham, T. E., Cieplak, P., Kollman, P. A., Case, D.\nA.,\"Continuum Solvent Studies of the Stability of DNA, RNA, and\nPhosphoramidate-DNA Helices\",J. Am. Chem. Soc.,vol. 120, pp.\n9401-9409, 1998.\n[35] Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee,\nM., Lee, T., Duan, Y., Wang, W., Donini, O., Cieplak, P., Srinivasan, J.,\nCase, D. A., Cheatham, T. E. III.,\"Calculating structures and free energies\nof complex molecules: combining molecular mechanics and continuum\nmodels\",Acc. Chem. Res.,vol. 33, pp. 889-897, 2000."]}

3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is a rate-controlling enzyme in the mevalonate pathway which involved in biosynthesis of cholesterol and other isoprenoids. This enzyme catalyzes the conversion of HMG-CoA to mevalonate and is regarded as a drug target to treat hypercholesterolemia. In this study, ten qualitative pharmacophore models were generated based on chemical features in active inhibitors of HMGR. The generated models were validated using a test set. In a validation process, the best hypothesis was selected based on the statistical parameters and used for virtual screening of chemical databases to find novel lead candidates. The screened compounds were sorted by applying drug-like properties. The compounds that satisfied all drug-like properties were used for molecular docking study to identify their binding conformations at active site of HMGR. The final hit compounds were selected based on docking score and binding orientation. The HMGR structures in complex with the hit compounds were subjected to 10 ns molecular dynamics simulations to refine the binding orientation as well as to check the stability of the hits. After simulation, binding modes including hydrogen bonding patterns and molecular interactions with the active site residues were analyzed. In conclusion, four hit compounds with new structural scaffold were suggested as novel and potent HMGR inhibitors.